Biogen beats Q3 estimates and raises lower end of 2026 EPS guidance
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Biogen Inc (NASDAQ:BIIB) on Wednesday reported third quarter adjusted earnings per share of $2.62, surpassing the analyst consensus of $2.02 by $0.60. Revenue reached $2.8 billion, exceeding the $2.64 billion estimate and representing an 11% increase from the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA strong earnings and revenue beat with improved guidance is a positive factor for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third quarter adjusted EPS was $2.62 versus a consensus of $2.02.
- 02Revenue reached $2.8 billion, above the $2.64 billion estimate, up 11%.
- 03The lower end of 2026 adjusted EPS guidance rose to $12.20 from $12.00.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets